The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

The endpoint management software provider has secured roughly $120m from strategic partner Salesforce, bumping its valuation up from $6.5bn to $9bn.

Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.

CAA and New Enterprise Associates have reportedly provided an initial $100m for Connect Ventures that could be upscaled to $400m.